Evidence map›Paper›PMID 41918886›Full record

ReviewFrontiers in cell and developmental biology2026

Advances in protein ubiquitination modification and immune evasion of breast cancer.

Yifan Wu, Jiangdong Jin, Xin Cheng, Ziyi Fu, Hui Xie

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yifan WuDepartment of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jiangdong JinDepartment of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xin ChengDepartment of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Ziyi FuNanjing Medical University, Nanjing, China.
Hui XieNanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein ubiquitination is one type of post-translational modification that can alter many properties of the protein-stability, activity, subcellular location, binding affinity for other proteins, etc. It has been involved in almost all life activities, including immune response regulation, DNA damage repair, cell cycle regulation, cell proliferation, apoptosis, and protein degradation. Moreover, it is associated with many kinds of disease, such as neurodegenerative diseases, various tumors, immune diseases, and metabolic diseases. Recent reports revealed that protein ubiquitination plays a key role in the breast cancer (BC) immune evasion. "Immune evasion" refers to the ability of tumor cells/pathogens to evade recognition and attack by the immune system through different mechanisms; it includes three interconnected processes: "immune editing," "antigenic variation," and "immunosuppressive molecules expression." These three points lead to the difficulty for the body to clear the transformed cells/pathogens promptly. Here, we summarize the mechanisms of protein ubiquitination in breast cancer immune evasion and explore new strategies targeting protein ubiquitination to combat BC.

Indexed as

breast cancerdeubiquitinating enzymes (DUBs)immunotherapyprotein ubiquitination modificationtumor immune evasion

Identifiers

PMID41918886
PMCPMC13033789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.